Alembic

When is the next results date for Alembic?

No Upcoming Board Meetings

What is the bonus history of the Alembic?

Alembic Ltd had a bonus issue of 1:1 announced on September 27, 2013, with a record date of September 30, 2013, allowing shareholders to double their holdings by receiving an additional share for each share held.

Alembic Ltd has a bonus history that includes a 1:1 bonus issue announced with an ex-date of September 27, 2013. The record date for this bonus was September 30, 2013. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time.

Has Alembic declared dividend?

Yes, Alembic Ltd has declared a dividend of 120%, amounting to ₹2.4 per share, with an ex-date of August 5, 2024. The company has shown strong long-term performance, particularly with a total return of 116.15% over the past five years.

Alembic Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 120%<BR>- Amount per share: 2.4<BR>- Ex-date: 05 Aug 24<BR><BR>Dividend Yield: 2.25%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -18.81%, with a dividend return of 0%, resulting in a total return of -18.81%.<BR><BR>For the 1-year period, the price return was 14.5%, the dividend return was 2.33%, leading to a total return of 16.83%.<BR><BR>Over the 2-year period, the price return was 63.92%, with a dividend return of 6.28%, culminating in a total return of 70.2%.<BR><BR>In the 3-year period, the price return was 63.4%, the dividend return was 10.83%, which resulted in a total return of 74.23%.<BR><BR>For the 4-year period, the price return was -10.93%, with a dividend return of 5.17%, leading to a total return of -5.76%.<BR><BR>In the 5-year period, the price return was 107.05%, the dividend return was 9.10%, resulting in a total return of 116.15%.<BR><BR>Overall, Alembic Ltd has declared a significant dividend of 120%, and while the total returns vary across different periods, the company has shown strong performance over the longer term, particularly in the 5-year period.

Is Alembic overvalued or undervalued?

As of January 29, 2021, Alembic is considered very expensive and overvalued, with a PE ratio of 9.24, an EV to EBITDA of 30.14, and a year-to-date stock decline of 14.93%, indicating that its valuation does not align with industry standards despite comparable PE ratios to peers.

As of 29 January 2021, Alembic's valuation grade has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 9.24, an EV to EBITDA of 30.14, and a PEG ratio of 0.59, which suggest that while the earnings are relatively low compared to the price, the growth expectations are not sufficiently high to justify the current valuation.<BR><BR>When compared to peers in the realty sector, Alembic's PE ratio is on par with its competitors, but its EV to EBITDA ratio is notably high, indicating potential overvaluation. For instance, if we consider similar companies, they may have lower EV to EBITDA ratios, which could suggest that Alembic's pricing does not align with industry standards. Additionally, Alembic's recent stock performance shows a decline of 14.93% year-to-date, contrasting with a 5.60% rise in the Sensex, further reinforcing the notion that the stock may be overvalued in the current market environment.

Who are the peers of the Alembic?

Alembic's peers include Ajmera Realty, Kolte Patil Dev., EFC (I), Ashiana Housing, Arvind SmartSp., AGI Infra, Unitech, Omaxe, and Elpro Internatio. In terms of performance, Alembic has a 1-year return of -21.16%, better than Ashiana Housing's -22.34%.

Peers: The peers of Alembic are Ajmera Realty, Kolte Patil Dev., EFC (I), Ashiana Housing, Arvind SmartSp., AGI Infra, Unitech, Omaxe, and Elpro Internatio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ashiana Housing, while Average management risk is found at Ajmera Realty, Kolte Patil Dev., EFC (I), Alembic, Arvind SmartSp., AGI Infra, and Elpro Internatio, and the rest. Growth is Excellent at EFC (I), Good at Alembic and Elpro Internatio, and Below Average at Ajmera Realty, Kolte Patil Dev., Ashiana Housing, Arvind SmartSp., Unitech, and Omaxe, and the rest. Capital Structure is Excellent at Ashiana Housing and Alembic, Good at Arvind SmartSp. and AGI Infra, and Below Average at Ajmera Realty, Kolte Patil Dev., EFC (I), Unitech, Omaxe, and Elpro Internatio, and the rest.<BR><BR>Return Snapshot: AGI Infra has the highest 1-year return at 132.12%, while Ashiana Housing has the lowest at -22.34%. Alembic's 1-year return is -21.16%, which is slightly better than Ashiana Housing's. Additionally, the six-month return is negative for Alembic, Ashiana Housing, Arvind SmartSp., Unitech, and Elpro Internatio.

Who are in the management team of Alembic?

As of March 2023, the management team of Alembic includes Chirayu R Amin (Chairman), Malika C Amin (Managing Director & CEO), and several directors, including independent members. They oversee the company's operations and strategic direction.

As of March 2023, the management team of Alembic includes the following members:<BR><BR>1. Chirayu R Amin - Chairman (Non-Executive)<BR>2. Malika C Amin - Managing Director & CEO<BR>3. C P Buch - Independent Director<BR>4. Udit Amin - Director<BR>5. Abhijit Joshi - Director<BR>6. Sameer Khera - Independent Director<BR>7. Drigesh Mittal - Company Secretary & Compliance Officer<BR>8. Rati Desai - Independent Director<BR>9. Mayank Amin - Independent Director<BR>10. Girish Hirode - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Alembic do?

Alembic Ltd is a manufacturer of bulk drugs and pharmaceuticals for human and animal healthcare, with a market cap of INR 3,083 Cr. As of March 2025, it reported net sales of 603 Cr and a net profit of 684 Cr, with a P/E ratio of 10.00.

Overview:<BR>Alembic Ltd is a manufacturer of bulk drugs and pharmaceuticals formulations in human and animal healthcare, operating in the Realty industry within the Small Cap market-cap bracket.<BR><BR>History:<BR>Alembic Ltd has a long-standing presence in the pharmaceutical sector, with operations primarily focused on the manufacture of bulk drugs and real estate. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 603 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 684 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap value: INR 3,083 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 10.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 2.08%<BR>- Debt-Equity: -0.02<BR>- Return on Equity: 13.28%<BR>- Price to Book: 1.32<BR><BR>Contact Details:<BR>Address: Alembic Road, Vadodara Gujarat: 390003<BR>Tel: 91-0265-2280550<BR>Email: alembic.investors@alembic.co.in<BR>Website: http://www.alembiclimited.com

Who are the top shareholders of the Alembic?

The top shareholders of Alembic include Nirayu Limited with 63.06%, 49 Foreign Institutional Investors holding 1.66%, and individual investors owning 21.94%. There are no mutual funds or public shareholders among the top holders.

The top shareholders of Alembic primarily consist of its promoters, with Nirayu Limited holding the largest stake at 63.06%. Additionally, there are 49 Foreign Institutional Investors (FIIs) who collectively hold 1.66% of the company. Individual investors also have a significant presence, owning 21.94% of the shares. Notably, there are no mutual funds currently invested in Alembic, and there are no public shareholders listed among the top holders.

How big is Alembic?

As of 24th July, Alembic Ltd has a market capitalization of 3,056.00 Cr, with recent net sales of 221.88 Cr and net profit of 310.68 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Alembic Ltd has a market capitalization of 3,056.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 221.88 Cr, while the sum of Net Profit for the same period is 310.68 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 2,338.59 Cr and Total Assets totaling 2,503.00 Cr.

Are Alembic latest results good or bad?

Alembic's latest results show strong sequential growth with a net profit increase of 108.45% quarter-on-quarter, but year-on-year sales growth is modest at 5.58%, raising concerns about sustainability due to reliance on non-recurring income. Investors should exercise caution regarding the quality of these earnings.

Alembic's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹128.49 crores for Q2 FY26, which is a significant increase of 108.45% quarter-on-quarter and 6.17% year-on-year. This indicates strong sequential growth and a positive trend in profitability.<BR><BR>Net sales also saw a commendable sequential increase of 12.28%, reaching ₹55.86 crores. However, the year-on-year growth of 5.58% is relatively modest and raises concerns about the company's ability to expand its revenue base effectively.<BR><BR>Operating margins improved to 41.60%, reflecting better operational efficiency, but this improvement is somewhat overshadowed by the fact that a substantial portion of the profit before tax (76.57%) came from other income, which surged to ₹64.92 crores. This reliance on non-recurring income raises questions about the sustainability of the reported earnings.<BR><BR>Overall, while the results show some positive trends in profitability and operational efficiency, the heavy dependence on exceptional other income and the lackluster year-on-year sales growth suggest caution. Investors may want to consider the quality and sustainability of these earnings before making any decisions.

Should I buy, sell or hold Alembic?

How has been the historical performance of Alembic?

Alembic has shown significant growth from March 2023 to March 2025, with net sales increasing from 127.24 Cr to 221.88 Cr, and profit after tax rising from 80.62 Cr to 144.57 Cr. The company also improved its operating profit margin to 42.23% and consolidated net profit to 310.68 Cr by March 2025.

Answer:<BR>The historical performance of Alembic shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Alembic's net sales have increased from 127.24 Cr in March 2023 to 221.88 Cr in March 2025, reflecting a strong upward trend. Total operating income has similarly risen, reaching 221.88 Cr in March 2025, up from 127.24 Cr in March 2023. The company's operating profit (PBDIT) has also shown substantial growth, climbing from 104.60 Cr in March 2023 to 168.60 Cr in March 2025, with an operating profit margin of 42.23% in March 2025, compared to 31.7% in March 2023. Profit before tax increased from 86.80 Cr in March 2023 to 155.51 Cr in March 2025, and profit after tax rose from 80.62 Cr to 144.57 Cr in the same period. The consolidated net profit reached 310.68 Cr in March 2025, up from 190.65 Cr in March 2023. On the balance sheet, total assets grew from 2,204.58 Cr in March 2023 to 2,503.00 Cr in March 2025, while total liabilities increased from 2,204.58 Cr to 2,503.00 Cr. Cash flow from operating activities improved significantly, rising to 86.00 Cr in March 2025 from 38.00 Cr in March 2023. Overall, Alembic has demonstrated a robust financial performance with increasing revenues, profits, and asset growth over the observed period.

Is Alembic technically bullish or bearish?

As of December 1, 2025, Alembic's technical trend is mildly bearish, with mixed signals from indicators like MACD, RSI, and Bollinger Bands suggesting a cautious outlook and short-term weakness.

As of 1 December 2025, the technical trend for Alembic has changed from bearish to mildly bearish. The current stance is mildly bearish overall, driven by mixed signals across various indicators. The MACD shows a mildly bullish trend on the weekly chart but is mildly bearish on the monthly chart. The RSI indicates a bullish signal on the monthly timeframe, while the weekly shows no signal. Bollinger Bands and KST are both mildly bearish on the weekly and monthly charts. Daily moving averages remain bearish, suggesting short-term weakness. Dow Theory indicates no trend in both weekly and monthly perspectives. Overall, the indicators reflect a cautious outlook with a slight bearish bias.

Which are the latest news on Alembic?

Why is Alembic Ltd falling/rising?

As of 20-Jan, Alembic Ltd's stock price is Rs 92.00, down 3.21%, continuing a downward trend with significant underperformance over various time frames. The stock is trading below all key moving averages, indicating bearish sentiment, and has seen a notable decline in investor participation and confidence.

As of 20-Jan, Alembic Ltd's stock price is falling, currently at Rs 92.00, reflecting a decrease of Rs 3.05 or 3.21%. This decline is part of a broader trend, as the stock has underperformed significantly over various time frames, including a 6.17% drop over the past week and an 8.96% decrease year-to-date. The stock has been on a consecutive downward trajectory for four days, with a notable intraday low of Rs 91.45, indicating persistent selling pressure.<BR><BR>The stock's performance is also lagging behind the benchmark Sensex, which has only fallen by 1.73% over the past week. Additionally, the pharmaceuticals and drugs sector, to which Alembic belongs, has seen a decline of 2.1%. Investor participation appears to be waning, as evidenced by a 34.35% drop in delivery volume compared to the five-day average.<BR><BR>Furthermore, Alembic Ltd's moving averages indicate that it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the bearish sentiment surrounding the stock. Despite some positive long-term growth indicators, such as a 32.70% annual growth rate in net sales, the stock's valuation remains high with a Price to Book Value of 0.9, and it has generated a negative return of 27.76% over the past year. The lack of investment from domestic mutual funds, which hold 0% of the company, may also reflect a lack of confidence in the stock's current price and business outlook.